This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HARRIS BLINDER, M.D.; JULIUS BURSTEIN, M.D.; WILLIAM HOROWITZ, M.D.; EUGENE GERSH, M.D.; RAANAN SMELIN, M.D.

Arch Intern Med. 1950;86(6):917-933.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE NEED for parenteral quinidine therapy has long been recognized. Administration by the intramuscular or intravenous route is indicated in patients requiring this drug who are unable to take the preparation orally because of vomiting, shock or coma and in instances in which rapidity of effect is important.

Following Wenckebach's report¹ in 1914 on the value of quinine in the treatment of cardiac arrhythmias and Frey's subsequent demonstration² of the greater effectiveness of its dextroisomer, quinidine, various investigators have attempted to obtain a satisfactory parenteral preparation. In general, these solutions have been unsatisfactory because of their lack of stability. Recently, stable solutions of quinidine have become available.

We have studied the effects of quinidine lactate administered parenterally on 59 subjects divided into three groups. Group A consisted of 22 persons with normal hearts, group B of 15 with abnormal hearts (with regular sinus rhythm) and group C of . . . [Full Text PDF of this Article]

Author Affiliations
NEW YORK

From the service of Julius Burstein, M.D., Department of Electrocardiography, Morrisania City Hospital.

Footnotes
Quinidine lactate was supplied by Eli Lilly & Company, Indianapolis 6.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?